Sort by
Items per page

Send to

Choose Destination

Search results

Items: 8


Sirolimus attenuates disease progression in an orthologous mouse model of human autosomal dominant polycystic kidney disease.

Zafar I, Ravichandran K, Belibi FA, Doctor RB, Edelstein CL.

Kidney Int. 2010 Oct;78(8):754-61. doi: 10.1038/ki.2010.250. Epub 2010 Aug 4.


Metastatic Renal Cancer: What Role for Everolimus?

Belibi FA, Edelstein CL.

Clin Med Rev Oncol. 2010 Feb 18;2:4.


Novel targets for the treatment of autosomal dominant polycystic kidney disease.

Belibi FA, Edelstein CL.

Expert Opin Investig Drugs. 2010 Mar;19(3):315-28. doi: 10.1517/13543781003588491. Review.


Long-term rapamycin therapy in the Han:SPRD rat model of polycystic kidney disease (PKD).

Zafar I, Belibi FA, He Z, Edelstein CL.

Nephrol Dial Transplant. 2009 Aug;24(8):2349-53. doi: 10.1093/ndt/gfp129. Epub 2009 Mar 25.


Unified ultrasonographic diagnostic criteria for polycystic kidney disease.

Belibi FA, Edelstein CL.

J Am Soc Nephrol. 2009 Jan;20(1):6-8. doi: 10.1681/ASN.2008111164. Epub 2008 Dec 10. No abstract available.


Cyclic AMP promotes growth and secretion in human polycystic kidney epithelial cells.

Belibi FA, Reif G, Wallace DP, Yamaguchi T, Olsen L, Li H, Helmkamp GM Jr, Grantham JJ.

Kidney Int. 2004 Sep;66(3):964-73.


Cyclic AMP activates B-Raf and ERK in cyst epithelial cells from autosomal-dominant polycystic kidneys.

Yamaguchi T, Nagao S, Wallace DP, Belibi FA, Cowley BD, Pelling JC, Grantham JJ.

Kidney Int. 2003 Jun;63(6):1983-94.


The effect of caffeine on renal epithelial cells from patients with autosomal dominant polycystic kidney disease.

Belibi FA, Wallace DP, Yamaguchi T, Christensen M, Reif G, Grantham JJ.

J Am Soc Nephrol. 2002 Nov;13(11):2723-9.

Supplemental Content

Loading ...
Support Center